Based on the Biodesix Inc stock forecast from 3 analysts, the average analyst target price for Biodesix Inc is USD 3.00 over the next 12 months. Biodesix Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biodesix Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Biodesix Inc’s stock price was USD 0.57. Biodesix Inc’s stock price has changed by -2.51% over the past week, -20.79% over the past month and -54.24% over the last year.
No recent analyst target price found for Biodesix Inc
No recent average analyst rating found for Biodesix Inc
Company Overview Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, together marketed as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado. Read Less
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identif...Read More
Frequently Asked Questions About Biodesix Inc (BDSX) Stock
Based on ratings from 3 analysts Biodesix Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on BDSX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BDSX is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on BDSX's stock to indicate if its overvalued.
The last closing price of BDSX's stock was USD 0.57.
The most recent market capitalization for BDSX is USD 0.10B.
Based on targets from 3 analysts, the average taret price for BDSX is projected at USD 3.00 over the next 12 months.
This means that BDSX's stock price may go up by +424.48% over the next 12 months.
We can't find any ETFs which contains Biodesix Inc's stock.
As per our most recent records Biodesix Inc has 273 Employees.
Biodesix Inc's registered address is 919 West Dillon Road, Louisville, CO, United States, 80027.
You can get more information about it from Biodesix Inc's website at https://www.biodesix.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Biodesix Inc (BDSX) Stock
Based on ratings from 3 analysts Biodesix Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on BDSX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BDSX is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on BDSX's stock to indicate if its overvalued.
The last closing price of BDSX's stock was USD 0.57.
The most recent market capitalization for BDSX is USD 0.10B.
Based on targets from 3 analysts, the average taret price for BDSX is projected at USD 3.00 over the next 12 months.
This means that BDSX's stock price may go up by +424.48% over the next 12 months.
We can't find any ETFs which contains Biodesix Inc's stock.
As per our most recent records Biodesix Inc has 273 Employees.
Biodesix Inc's registered address is 919 West Dillon Road, Louisville, CO, United States, 80027.
You can get more information about it from Biodesix Inc's website at https://www.biodesix.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BDSX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
